myTomorrows Raises $29M from Avego to Expand Global AI Platform for Pre-Approval Therapy Access

Health technology company myTomorrows has announced a $29 million financing round led by Avego to accelerate its global expansion and enhance access to pre-approval treatments. The investment aims to expand the company’s integrated pharma solutions, designed to improve patient equity and accessibility to emerging therapies worldwide.

With over 300 million patients globally facing diseases with no approved treatments, and more than 10,000 therapies in development or awaiting approval, myTomorrows is addressing a critical healthcare challenge. The company’s platform helps bridge the gap between scientific innovation and patient access to investigational therapies, including clinical trials and expanded access programs (EAPs).

myTomorrows operates a unified AI-powered ecosystem connecting patients, physicians, trial sites, and BioPharma partners to simplify access to pre-approval treatments. The platform leverages artificial intelligence alongside expert human navigation to bring transparency, coordination, and actionable insight into the treatment discovery process.

The new funding will allow myTomorrows to strengthen its AI-driven infrastructure and deepen integration with BioPharma stakeholders to accelerate clinical development, enhance real-world evidence collection, and provide richer regulatory insight. “This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow’s therapies,” said Michel van Harten, CEO of myTomorrows. “Avego’s deep life sciences expertise, especially in BioPharma, will be instrumental as we scale our platform and broaden our global impact.”

Currently, myTomorrows supports more than 16,900 patients across 133 countries through its comprehensive AI platform. The system enables expert guidance, personalized treatment matching, and streamlined access to both clinical trials and expanded access programs. BioPharma partners benefit from trial recruitment support, EAP management, and real-world data capture, while trial sites gain unified referral tools and real-time tracking visibility.

By connecting every stakeholder in the healthcare ecosystem, myTomorrows is advancing a global framework for equitable, data-driven access to innovative therapies. Its AI-enabled platform continues to redefine how investigational treatments are discovered and delivered, ensuring that patients worldwide can benefit from tomorrow’s medical breakthroughs today.

Click here for the original news story.